You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Organized Lipid Matrix: Fatty Acids and Choline in CF

    SBC: AVANTI POLAR LIPIDS, INC.            Topic: N/A

    Individuals with cystic fibrosis (CF) and pancreatic insufficiency (PI) are prone to fat malabsorption, putting them at risk for caloric, essential fatty acid, and choline deficiency, which, in turn, may lead to growth failure and a poorer clinical course. Many subjects with CF have essential fatty acid deficiency, characterized by decreased levels of linoleic acid and an increased triene/tetraene ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  2. Antiviral Drugs for Lassa Fever Virus

    SBC: SIGA TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Hemorrhagic fever viruses are of serious worldwide health concern as well as potential biological weapons. Lassa fever virus in particular annually infects several hundred thousand individuals in West Africa, and the export of this pathogen outside of this region, either intentionally or unintentionally, presents a serious risk to the developed countries of the ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  3. Small Molecule Inhibitors of Smallpox Virus Replication

    SBC: SIGA TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Concern over the use of variola virus as a biological weapon has prompted interest in development of small molecule therapeutics for smallpox. Variola virus is highly transmissible and causes severe disease with high mortality rates. Currently, there is no FDA-approved drug for prevention or treatment of smallpox. The overall goal of this smallpox antiviral pro ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  4. Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD

    SBC: THERAPYX, INC.            Topic: NIAID

    Abstract TGF NanoCapis an oral combination of nanoparticulate transforming growth factor betaTGFand alltrans retinoic acidATRAin pre clinical development for treatment of inflammatory bowel diseaseIBDPhase I studies provided proof of principle for efficacy in a murine modelPhase II work optimized therapeutic protocolconfirmed efficacy in a second modelestablished scale up manufacturing methodscomp ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. DEVELOPMENT OF A WNT PATHWAY INHIBITOR FOR METASTATIC COLORECTAL CANCER

    SBC: Stemsynergy Therapeutic            Topic: 102

    ABSTRACT Colorectal cancerCRCrepresents the fourth most commonly diagnosed cancer withnew cases each yearUnfortunatelyCRC results in a disproportionate number of deathsprojected indue to advanced stage at diagnosisthe aggressive phenotype of the disease and lack of effective therapeuticsGreater thanof CRC patients possess activating mutations in the WNT signaling pathwayWNT pathway activation is a ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Novel IL-15 Superagonist Therapy for Bladder Cancer

    SBC: Altor BioScience, LLC            Topic: NCI

    Project SummaryBladder cancer is the fifth most common cancer in the U SUp toof patients initially present with non muscle invasive bladder cancerNMIBCconfined to the mucosa of the bladderThese patients are treated by tumor resection followed by intravesical chemotherapy or Bacillus Calmette Gu rinBCGtherapyDespite treatmentup toof patients will experience tumor recurrence andof theseaboutwill und ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Therapeutic Protein C Activator for Myocardial Ischemia

    SBC: ARONORA INC            Topic: NHLBI

    PROJECT SUMMARY Heart attackor acute myocardial infarctionAMIis a leading cause of death in the United Stateswith overvictims every yearThe most prevalent cause of AMI is progressive thrombotic coronary artery occlusionalso known as ST segment elevation myocardial infarctionSTEMIEarly therapy to promote heart reperfusion can dramatically improve outcomesWhile percutaneous coronary interventionPCIi ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Rapid Low Cost Phenotypic Antibiotic Susceptibility Testing.

    SBC: Specific Diagnostics, Inc.            Topic: NIAID

    Project Summary Antibiotic resistance has recently emerged as a global threat for healthcare systemsAn increasing number of pathogenic bacteria are acquiring antibiotic resistanceand new forms of resistance are continuously emerging with alarming speed across international boundariesIn the USalonethe Center for Disease Control and PreventionCDChas estimatedmillion patients per year are directly af ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Combining faster detection with ID: a new paradigm for mycobacterial culture

    SBC: Specific Diagnostics, Inc.            Topic: NIAID

    Project Summary Abstract TuberculosisTBis one of the leading causes of morbidity and mortality from infectious disease worldwide with an estimatedmillion cases of active TB andmillion deaths from the disease annuallyDespite emerging new technologiesculture remains the gold standard in TB diagnosis and therapeutic monitoringInthe World Health OrganizationWHOrecommended the use of a liquid culturing ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Development of an H2O2-inactivated chikungunya virus vaccine

    SBC: NAJIT TECHNOLOGIES INC            Topic: R

    Chikungunya virusCHIKVis an alphavirus that has gained significant attention due to its ability to cause large epidemics among susceptible populations and to be spread beyond endemic countries by international travelersAmong a population of approximatelyon the French island of La Reunionpeople were infected and overCHIKV related fatalities occurred during theoutbreakLikewisean estimatedmillion peo ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government